{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:20:50Z","timestamp":1790961650436,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ijrobp.2009.01.081","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T08:25:14Z","timestamp":1246350314000},"page":"43-49","source":"Crossref","is-referenced-by-count":42,"title":["Brachytherapy or Conformal External Radiotherapy for Prostate Cancer: A Single-Institution Matched-Pair Analysis"],"prefix":"10.1016","volume":"76","clinical-trial-number":[{"clinical-trial-number":"nct00407875","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tom","family":"Pickles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. James","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2009.01.081_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijrobp.2006.07.1382","article-title":"15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience","volume":"67","author":"Sylvester","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijrobp.2007.10.004","article-title":"Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes","volume":"71","author":"Cahlon","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijrobp.2007.10.019","article-title":"A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant","volume":"71","author":"Eade","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2007.07.323","article-title":"Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer. ASTRO Annual Scientific Meeting. Vol. 69. Los Angeles, CA","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib5","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ijrobp.2008.07.042","article-title":"Evaluation of dosimetric parameters and disease response in 1006 consecutive patients treated with 125-Iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/srao.2002.28667","article-title":"Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes","volume":"12","author":"Blasko","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2004.02.011","article-title":"125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy","volume":"60","author":"Keyes","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib8","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ijrobp.2006.03.020","article-title":"A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems","volume":"65","author":"Williams","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2004.09.048","article-title":"PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy","volume":"62","author":"Bates","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy. Sequential outcomes of 712 men","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S0167-8140(06)80967-9","article-title":"Timing of androgen deprivation therapy after radical radiotherapy failure: A survey of Canadian practitioners","volume":"80","author":"Cheung","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.urology.2008.07.064","article-title":"Population based study of biochemical and survival outcomes after permanent (125)I brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2003.11.024","article-title":"Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging","volume":"59","author":"Pickett","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<328::AID-CNCR16>3.0.CO;2-2","article-title":"Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen","volume":"79","author":"Crook","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ijrobp.2008.08.049","article-title":"Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and\/or external beam radiotherapy","volume":"74","author":"Stock","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib18","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2002.03.061","article-title":"Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer","volume":"20","author":"D'Amico","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib19","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Prostate Specific Antigen\u00a0Working Group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib21","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.299.8.898-c","article-title":"Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate","volume":"299","author":"Zietman","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib23","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.2007.11.9768","article-title":"The Titanic and the iceberg: prostate proton therapy and health care economics","volume":"25","author":"Zietman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0360-3016(01)02812-7","article-title":"Predictive factors of urinary retention following prostate brachytherapy","volume":"53","author":"Bucci","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2004.12.056","article-title":"Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?","volume":"63","author":"Macdonald","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2005.04.056","article-title":"Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?","volume":"64","author":"Keyes","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0360-3016(03)00777-6","article-title":"Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy","volume":"58","author":"Liu","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2004.09.016","article-title":"Urinary incontinence in prostate cancer patients treated with external beam radiotherapy","volume":"74","author":"Liu","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0360-3016(95)00041-V","article-title":"Complicating issues in complication reporting","volume":"31","author":"Peters","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.01.081_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): An open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609004210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609004210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:55:42Z","timestamp":1545155742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301609004210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0360301609004210"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2009.01.081","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}